Patient Facing Nuclear Medicine

Phillip Koo | October 27, 2018

The field of nuclear medicine has seen a resurgence in relevance especially in the area of prostate cancer imaging and therapy.  Dr. Evan Yu adeptly summarizes the promising potential of PSMA radioligand therapies in his October 2018 post in the Clinical Trials section of UroToday.  We look forward to seeing his future article regarding diagnostic trials evaluating various PSMA targeted agents.


Phillip J. Koo, MD, FACS

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging.

State-of-the-industry video lectures by leading urology experts
Conference Coverage
Recent data from conferences worldwide

EAU 2019 Prostate Cancer

SUFU WM 2019

ASCO GU 2019 Prostate Cancer

ESOU 2019 Prostate Cancer

ESMO 2018 Prostate Cancer

AUA 2018 Northeastern Section

SIU 2018

WCE 2018

EAU 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

SUO 2017 - Prostate Cancer

SUO 2017 - Bladder Cancer

2017 Quality Improvements Summit

ESMO 2017 Prostate Cancer

CUA 2017


ASCO 2017 Prostate Cancer

ASCO GU 2017 Penile, Urethral & Testicular Cancer

ASCO GU 2017 Kidney Cancer

Editor selected abstracts and commentaries

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.